Newsbenzinga
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations
· Published
Article summary
Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.
An excerpt from the original article.
Comments —
Loading comments…